Oyster Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-12-2024
- Paid Up Capital ₹ 0.95 M
as on 24-12-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.65 Cr
as on 24-12-2024
- Revenue -67.47%
(FY 2019)
- Profit -213.58%
(FY 2019)
- Ebitda -223.15%
(FY 2019)
- Net Worth -5.20%
(FY 2019)
- Total Assets -14.05%
(FY 2019)
About Oyster Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹1.65 Cr.
Nalini Garg and Ram Garg serve as directors at the Company.
- CIN/LLPIN
U24233HP2006PTC030399
- Company No.
030399
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Oyster Pharma Pvt Ltd offer?
Oyster Pharma Pvt Ltd offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Antiseptic Gel, Lotion & Cream, Povidone Iodine Ointment, Aceclofenac Tablet, Aceclofenac Paracetamol Serratiopeptidase Tablet, Nutraceuticals & Dietary Supplements, Protein Powder, Multivitamin Tablets & Capsules, Ayurvedic,Herbal Products & Medicine.
Who are the key members and board of directors at Oyster Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nalini Garg  | Director | 06-Jul-2011 | Current |
| Ram Garg | Director | 23-Jun-2006 | Current |
Financial Performance of Oyster Pharma.
Oyster Pharma Pvt Ltd, for the financial year ended 2019, experienced significant reduction in revenue, with a 67.47% decrease. The company also saw a substantial fall in profitability, with a 213.58% decrease in profit. The company's net worth dipped by a decrease of 5.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oyster Pharma?
In 2019, Oyster Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 05 Jul 2013 | ₹1.65 Cr | Open |
How Many Employees Work at Oyster Pharma?
Oyster Pharma has a workforce of 5 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oyster Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oyster Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
